Latest

New “Right-to-Try” Law Challenges FDA Oversight

Right-to-Try bill sent to White House for President’s signature after passage by Congress.

Cloud Levels Playing Field for Emerging Life Sciences Companies

A discussion of the benefits that a cloud-based strategy has to offer.

Strategic Medical Affairs: Building the Capabilities to Deliver Value

This article is a roundtable consisting of global Medical Affairs leaders to discuss the potential of Medical Affairs as a key value driver and the role MAPS will play in bringing that potential to fruition.

Trump Drug Pricing Plan Outlines Rule Changes Pharma Can Live With

After months of expectations and repeated delays, President Trump formally announced his strategy for making prescription medicines more affordable and accessible in the U.S.

Pharm Exec Video

The Fundamental Disconnect Between Pharma and Technology

Otsuka Pharmaceuticals' William Carson explains the growing pains the company and its technology partner went through in reaching FDA approval for their digital medicine system.

Pharma’s Data Tsunami Problem

William Carson, Otsuka Pharmaceuticals' president & CEO of development and commercialization, talks about the industry's challenges in tackling the huge amounts of collected data.

Healthcare Robotics: Meet Mabu Your Personal Health Companion

Take a sneak peek at what the future of home healthcare could look like with the use of robotics and artificial intelligence.

New & Noteworthy

Brands of the Year: Promise and Challenge

In its 12th annual feature, Pharm Exec profiles a new round of biopharma products that are making waves in five key areas in healthcare and R&D.

Patient Advocacy: an Overlooked Strategy for Achieving Equitable Market Success?

Ellen Coleman outlines the highlights of a recent webinar on ensuring that patient advocacy is a key element of a market access strategy.

Attribution: Mission-Critical for Digital Marketing Measurement

Digital attribution models have transformed the way e-commerce companies measure and optimize ad spend. So why have medical marketers been slow to adopt them, asks Kevin Troyanos.

Closing Pharma’s Digital Divide

Overcoming the challenges of digital brand management will involve choices in spending and channels.

Sales & Marketing

Attribution: Mission-Critical for Digital Marketing Measurement

Digital attribution models have transformed the way e-commerce companies measure and optimize ad spend. So why have medical marketers been slow to adopt them, asks Kevin Troyanos.

Closing Pharma’s Digital Divide

Overcoming the challenges of digital brand management will involve choices in spending and channels.

Patient Empowerment and the Future of Pharma Advertising

With digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Digital Transformation: What's the Cost of Doing Nothing?

Right now, the smartest incumbents are channeling the forces of disruption to their own ends, leading digital transformation in order to avoid being left behind, writes Tony Owens.

Building New York Into the Next Biotech Hotspot

Known as the city that never sleeps, attracting and keeping the scientific breakthroughs in-state is something that’s keeping New York economic and academic developers up at night.

Asembia 2018 Insights: Consolidation Madness, Carrots and Sticks

Curant Health executive discusses key insights from Asembia 2018.

Gauging the Collaborative Spirit in European Health

Pair of EU meetings, while well-meant, offered little action and beg the question—what’s the true merit in working together?

Big Data & Japan's Aging Population: Opening the Door for US Pharma

Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.

Interviews

Q&A: Ann Aerts from Novartis Foundation

Dr. Ann Aerts, head of the Novartis Foundation, Switzerland talks with Pharm Exec about the Novartis Foundation initiatives.

Bridging Science & Strategy: An Investor’s Eye

Pharm Exec speaks with Tim Sullivan, who brings that sought-after melding of business and scientific perspectives to his role as chief financial officer for Apellis.

Enhancing the Focus: Halozyme's Helen Torley

CEO Helen Torley talks to Pharm Exec about her vision for Halozyme as a multi-product oncology biotech.

Regulatory

New “Right-to-Try” Law Challenges FDA Oversight

Right-to-Try bill sent to White House for President’s signature after passage by Congress.

Improving Regulatory Resource Management through Systematic Measurement

As submissions complexity intensifies, the key to better resource management is better measurement, writes Adrian Leibert.

Trump Drug Pricing Plan Outlines Rule Changes Pharma Can Live With

After months of expectations and repeated delays, President Trump formally announced his strategy for making prescription medicines more affordable and accessible in the U.S.

From the Editor

So Much Depends on the Physician

Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.

The New Talent Trajectory

Pharma's evolving landscape in recent years has created the need to recruit experts from outside of industry—and establish new pathways for traditional executive roles in the life sciences.

lorem ipsum